

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C12N 5/02		A1	(11) International Publication Number: <b>WO 96/26266</b>  (43) International Publication Date: 29 August 1996 (29.08.96)
<p>(21) International Application Number: PCT/EP96/00720</p> <p>(22) International Filing Date: 20 February 1996 (20.02.96)</p> <p>(30) Priority Data: 08/393,338 23 February 1995 (23.02.95) US 08/393,336 23 February 1995 (23.02.95) US</p> <p>(71) Applicant: QUEST INTERNATIONAL B.V. [NL/NL]; Huizerstraatweg 14, NL-1411 GP Naarden (NL).</p> <p>(72) Inventors: BLOM, Wim, R.; Vuurvlinderberg 50, NL-3994 WI Houten (NL). KUNST, Anthonie; Weegbree 41, NL-1273 AN Huijen (NL). HAKKAART, Marcellinus, Jacobus, J.; Surinamelaan 18, NL-1213 VN Hilversum (NL). LULI, Gregory, W.; Unit # 3, 121 Kristin Circle, Schaumburg, IL 60195 (US). VAN SCHIE, Bartholomeus, Josef; Mos 18, NL-1273 CP Huijen (NL).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: PEPTIDES FOR TISSUE AND CELL CULTURE MEDIA</p> <p>(57) Abstract</p> <p>The invention relates to a method and culture medium for in vitro culturing eucaryotic cells requiring glutamine, which comprises the use of a protein hydrolysate obtained by enzymatic hydrolysis of a protein material. The protein hydrolysate has a free amino acid level of less than 15 % by weight and the protein hydrolysate have molecular weight below 44 kD. The protein hydrolysate preferably contains at least 20 % of glutamine residues. Also, preferably at least 90 % by weight of the peptides have a molecular weight below 1000 D and the average peptide chain length preferably is below 15 amino acid residues.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Peptides for tissue and cell culture media.

Background of the invention

5

The present invention relates to a novel method for proliferating, propagating, maintaining and culturing of eucaryotic cells and to suitable culture media for this purpose. In particular the present invention relates to 10 such method comprising the use of protein hydrolysate, prepared from a protein using one or more hydrolytic enzymes, as a basis of a medium for eucaryotic cells and to culture media comprising such protein hydrolysate.

15

Description of related art

Existing media for in vitro culturing of eucaryotic cells (culture media) in general comprise mixtures of amino 20 acids, vitamins, carbohydrates and minerals. The prior art has described the need for the amino acid L-glutamine as an essential ingredient in such media. Illustrative of this art is US 3,579,423 (Yamane et al). Culture media contain relatively large amounts of L-glutamine. Typically it is 25 used in a cell growth and maintenance medium at a concentration of about 2 mM. It is an important energy source in proliferating eucaryotic cells and it also serves as both a carbon and a nitrogen source, especially for purine and pyrimidine synthesis.

30

The use of glutamine as an energy source in cultured mammalian cells proceeds via deamidation of glutamine by glutaminase to yield glutamate and ammonia. Glutamate then undergoes transamination to produce  $\alpha$ -ketoglutaric acid

which is incorporated into the energy yielding Krebbs tricarboxylic acid cycle.

5 The incorporation of glutamine in a liquid cell culture medium however suffers from the disadvantage that glutamine is not very stable in the free amino acid form. It is well known to rapidly decompose into ammonia and pyroglutamic acid. Recently Heeneman et al (J. Immunological Methods 116, 85-91, 1993) found that as a consequence of this

10 decomposition all tested commercial media contained significantly less glutamine than prescribed. In addition Heeneman et al point to the fact that the formed ammonia can be toxic to cultured cells.

15 When glutamine is incorporated in a peptide it does not decompose, provided that the glutamine residue is not present at the amino terminal end since only in this position the glutamine residue can decompose into a pyroglutamic acid residue and ammonia.

20 The prior art has described the use of small synthetic peptides for cell growth in US 4,235,772 (Hugo) and US 4,058,512 (Sievertsson et al). These peptides contain small amounts of L-glutamine and are thus not a good source for

25 this essential amino acid. Heeneman (*vide supra*) and K. Brand et al (Metabolism 38(8), Suppl.1, 1989 29-33) recommend the use of the dipeptide Glycyl-L-glutamine as a source of glutamine. Brand, however, reports that on a glutamine basis more of the dipeptide (up to 6 times) is

30 needed than of free glutamine to obtain the same result. This dipeptide can only be suitably obtained by synthesis. All synthetic peptides suffer from the disadvantage that they are expensive and have limited availability.

There is abundant prior art on the preparation of peptides by hydrolysis of protein. In general two types of such protein hydrolysates can be distinguished: (1) hydrolysates comprising peptides with a chain length above 15 amino

5 acids and a relatively low level of free amino acids (generally below 10%); and (2) hydrolysates comprising peptides with a chain length below 15 amino acids and a relatively high level of free amino acids (about 20% or more).

10

Hydrolysates of the first group are used in food applications as functional ingredients e.g. emulsifiers or aeration aids. It is well known that for optimal properties peptide chains above 15 amino acid residues (e.g. 15-50)

15 are required. The presence of free amino acids should be avoided as these give an unwanted savoury taste and smell to the product. Consequently these type of hydrolysates comprise peptides with a chain length well above 15 amino acids and a level of free amino acids below about 10%.

20

Hydrolysates of the second group are in food applications mainly used in infant and clinical nutrition formulae where a low allergenicity and preferably reduced bitterness is required. For these purposes the product should contain

25 small peptides and this is achieved with enzyme preparations having both endo- and exo-peptidase activity. Due to the action of the exopeptidases the amount of free amino acids is strongly increased to levels of about 20% or higher.

30

In the fermentation industry hydrolysates of the second group with high amounts of free amino acids (20% or higher) are used as a relatively cheap source of amino acids in culture media for microorganisms. Protein hydrolysates with 35 a high level of free amino acids, however, also suffer from

the disadvantage that free glutamine decomposes into pyro-glutamic acid and the toxic ammonia and thus, they are not very well suited for application in eucaryotic cell culture media.

5

The prior art (e.g. *Animal Cell Culture, A practical approach*, second edition, ISBN 0-19-963213-8) describes the use of lactalbumin hydrolysates (prepared with pancreatin which contains both endo- and exopeptidase activity) or 10 peptones (hydrolysates with a very high level of free amino acids) in cell culture media, but only as supplements and not as the main source of glutamine or other amino acids.

The prior art has described various hydrolysates derived 15 from wheat gluten, which contain the glutamine residue in the molecule; illustrative are US 3,852,479 (Yokotsuka et al), 3,932,671 (Yokotsuka et al) and 4,100,151 (Adler-Nissen). These products are used in foods. Tanabe et al, *J. Food Biochem.*, 16(4), 1993 235-48 investigated the use of a 20 high-glutamine oligopeptide, obtained by hydrolysis of gluten, as a glutamine source in enteral nutrition through rat feeding studies..

There appears to be no description in the prior art of the 25 use in culture media for eucaryotic cells of higher peptides than (synthetic) dipeptides, of peptide mixtures obtained from protein hydrolysates, or of intact proteins containing glutamine as the main or only source of glutamine and/or other amino acids.

30

Objects of the invention

It is an object of the present invention to provide a novel 35 method for in vitro culturing of eucaryotic cells. In

particular it is an object of the present invention to economically provide amino acids, particularly glutamine, in a form in which they can be taken up by eucaryotic cells which is stable in aqueous solution under the conditions

5 used to culture eucaryotic cells, which is easy to use, can be sterilised by conventional means and is free of toxic and inhibitory effects. Furthermore, it is an object of the present invention to provide stable, glutamine providing culture media for culturing eucaryotic cells, which are

10 easy and economic to produce. Other objects of the invention will become apparent to those skilled in the art.

Detailed description of the invention

15 The present invention provides a method for in vitro maintaining or growing eucaryotic cells by use of a culture medium comprising a glutamine containing protein hydrolysate, obtained by enzymatic hydrolysis of a protein

20 material, wherein the protein hydrolysate has a free amino acid level of less than 15% by weight of the total proteinaceous material.

Furthermore, the invention provides culture media for in

25 vitro maintaining or growing eucaryotic cells which comprise a glutamine containing protein hydrolysate, obtained by enzymatic hydrolysis of a protein material, wherein the protein hydrolysate has a free amino acid level of less than 15% by weight of the total proteinaceous

30 material.

The glutamine containing protein hydrolysates used for the purposes of this invention are obtained according to methods known in the art i.e. by enzymatic hydrolysis of

35 protein, which may be of plant or animal origin, such as

milk protein (casein, albumin, etc.), meat protein, soy protein or cereal protein (wheat, rice, maize, etc.). Since most commonly used cell culture media contain high levels of glutamine, the protein hydrolysate for the purposes of 5 this invention should preferably have a level of glutamine residues of 20% by weight or more. A protein source which is high in glutamine residues is therefore generally preferred as the starting material, such as cereal protein, more particularly wheat gluten or its subfractions glutenin 10 and gliadin which are known to contain 25-30% of glutamine.

The hydrolytic enzyme or enzymes used for the hydrolysis of the protein starting material may be of animal, plant, yeast, bacterial or fungal origin. Preferably enzymes are 15 used which have a low exo-peptidase activity so as to minimize the liberation of free amino acids. Suitable enzymes are e.g. Pepsin, Alcalase or Orientase.

The protein hydrolysates should have a level of free amino 20 acids below 15% by weight, preferably below 10%. For specific purposes a level of 4% or less may be required. The peptides should have a molecular weight below 44 kD. Preferred are those protein hydrolysates in which the majority of the peptides have a molecular weight below 1000 25 D, more preferably at least 90% by weight of the protein hydrolysate has a molecular weight below 1000 D. Also, the average peptide chain length in the protein hydrolysate should preferably be below 15 amino acid residues, more preferably below 10. On the other hand the minimum 30 molecular weight of the peptides should preferably be above 200 D.

Conventional culture media contain vitamins, a carbohydrate source and (a source of) amino acids. The pH of the media 35 preferably is between 6 and 8. As outlined above, the prior

art has used various hydrolysed proteins such as milk protein (casein) for culture media intended for culturing microorganisms. Microorganisms have the necessary enzymes to enable growth on complex protein. However, higher 5 eucaryotic cells, though comprising subsets of cells having vastly different characteristics, in general lack the capacity for utilising complex protein. It was thus unexpected that the protein hydrolysates according to the present invention were able to support the culturing of 10 eucaryotic cells. There is no clear explanation for this observation, but it may be hypothesised that eucaryotic cells apart from the sodium dependant amino acid uptake system (comprising a carrier protein) possess a mechanism via which small peptides can be transported into the cell.

15

The culture media of the present invention include ingredients conventionally found in media for culturing eucaryotic cells i.e. vitamins, minerals, carbohydrates, growth promotors and amino acids. Rather than free 20 L-glutamine they contain the protein hydrolysates as the main or only source thereof. The protein hydrolysates can also be used as the source of other essential amino acids in the culture media.

25 The eucaryotic cells are preferably animal cells, more preferably mammalian (such as human) or insect cells.

Eucaryotic cells are often cultured with the aim of having them produce certain valuable compounds, particularly for 30 pharmaceutical or diagnostic purposes. It is also well known to those skilled in the art that eucaryotic cell cultures generally show a growth phase, in which the number of cells increases, followed by a stationary phase in which the number of cells remains more or less constant. It is 35 often in this stationary phase that production of the

desired compounds is greatest in the culture. It has been found that the protein hydrolysates according to the invention not only act favourably on the growth phase, but particularly also on the production phase, i.e. increase 5 the production of the desired compound by a given cell mass in a given time, compared with prior art culture media containing free glutamine.

10 The culture media according to the present invention may be provided as complete kits including a container in which the cells to be cultured can be introduced. The culture medium can be supplied as a dry mix to which water is added to produce a liquid culture medium ready for use.

15 Alternatively the medium may be provided as a ready to use sterile liquid to which the cells may be added directly.

The latter obviates the need for sterilization of the medium after preparation. Unlike the prior art media the liquid media according to the invention may be shipped and stored without deterioration, due to the stable form in 20 which glutamine is present.

The analytical methods to determine the various relevant parameters are described below.

25 **Analytical methods.**

Definitions

TN : Total Nitrogen.

30 AN : Alpha amino Nitrogen.

EN : Epsilon amino Nitrogen.

AEN : The sum of alpha and epsilon nitrogen.

PN : Nitrogen in (potential) peptide bonds (PN thus includes all AN).

35 FAA : free amino acid level.

F : average amount of Nitrogen per amino acid residue in a protein.

PCL : average peptide chain length.

Determination of parameters

AEN can be determined via methods such as the TNBS method (cf. J. Adler-Nissen, Enzymatic Hydrolysis of Food

5 Proteins, Elsevier Applied Science Publishers, 1986) or via formol titration.

TN can be determined via the well known Kjeldahl method.

EN is only present in the side chain of lysine so it is equal to the amount of lysine in the product.

10 FAA is determined using an amino acid analyser.

AN can be calculated from the AEN (as determined via TNBS or formol titration) and the amount of lysine (=EN) in the protein hydrolysate:

$$AN = AEN - EN \quad (1)$$

15 PN can be approximated from TN using the average amount of nitrogen (F) per amino acid.

$$PN = TN/F \quad (2)$$

Most amino acids only have an alpha nitrogen atom but trp, lys, asn and gln have 1 extra nitrogen in the side chain,

20 his has 2 extra nitrogen and arg has 3 extra nitrogen in the side chain. In Table 1 the average amounts of N per amino acid (F) for a number of common proteins are given.

Table 1. Some data on common proteins.

25

	F	% lysine
casein	1.32	8.23
Whey protein	1.26	10.12
Soy protein	1.28	6.50
Gluten	1.43	1.58

Calculation of the average peptide chain length

The average peptide chain length can be calculated from AN and PN:

5  $PCL = PN/AN$  (3)

Combining eq. 3 with eq. 2 gives:

$PCL = TN/(F*AN)$  (4)

Combining eq. 4 with eq. 1 gives:

$PCL = TN/(F * (AEN-EN))$  (5)

10 With eq. 5 the average peptide length in a hydrolysate is calculated in which also the FAA is taken into account. Strictly spoken an amino acid is not a peptide and FAA thus should not be included in the calculation of the average PCL. To calculate the average peptide length of the non FAA 15 fraction, TN and AN of this fraction are required.

Rewriting eq. 4 for the peptide fraction gives:

$PCL_{pep} = TN_{pep}/(F*AN_{pep})$  (6)

in which:

$TN_{pep} = TN - TN_{FAA}$  (7)

20  $TN_{FAA} = F * FAA$  (8)

$AN_{pep} = AN - FAA$  (9)

Combining eq. 6 with eq 1, 7, 8 and 9 results in:

25 
$$PCL_{pep} = \frac{TN/F - FAA}{AEN - EN - FAA}$$
 (10)

in which TN, AN, AEN, EN and FAA are given in mmol per weight unit.

**2. Determination of molecular weight distribution.**

30

There are a number of methods to determine the molecular weight distribution. An easy and convenient method uses gel permeation chromatography. There are many, all slightly different procedures reported in the literature.

35 For the purposes of this invention use was made of a Protein-Pak 60 column from Waters with a length of 30 cm

and an internal diameter of 7.8 mm and a Protein-Pak 125 Bulk Packing guard column. The column is eluted with a 0.1 M potassium phosphate buffer with pH 7.0 at a flow rate of 1.0 ml/min. For analysis 20  $\mu$ l samples containing 0.2-0.5 mg product per ml elution buffer are injected on the column. Protein and peptide peaks are detected at 214 nm. The amount of material within a molecular weight range is determined from the surface under the chromatogram in that molecular weight range.

10

### **3. Determination of glutamine levels in protein hydrolysates**

Due to the instability of free glutamine it is not possible 15 to determine the amount of glutamine in a protein based product via the normal procedure to determine the amino acid composition. In this procedure the protein based product is treated with 6N HCl to hydrolyse it into free amino acids of which the amount can then be determined with 20 an amino acid analyser. During the 6N HCl hydrolysis glutamine decomposes into ammonia and pyroglutamate which is subsequently converted in glutamic acid.

An indirect method to analyse the amount of glutamine in a 25 hydrolysate is to determine the amount of  $\text{NH}_3$  liberated during the acid hydrolysis as described by MacRitchie (J. Food Technol. 14, 595-601, 1979). Since  $\text{NH}_3$  is not only liberated from glutamine but also from asparagine (which decomposes into ammonia and aspartic acid) the amount of 30 mmol  $\text{NH}_3$  liberated from a protein sample equals the amount of mmol asparagine + glutamine (Asn+Gln) in that protein sample. Since the origin of the liberated  $\text{NH}_3$  cannot be determined it has to be assumed that the proportion of amidated groups is the same in the two types of chains.

We have tested the reliability of this method by determination of the amount of  $\text{NH}_3$  liberated from casein and whey protein and comparing the results with the theoretical results calculated on basis of the known 5 compositions and amino acid sequences of the individual caseins and whey proteins. In addition the amount of  $\text{NH}_3$  liberated from gluten was determined. The results are summarised in Table 2. It can be seen that there is a good agreement between the  $(\text{Asn}+\text{Gln})/(\text{Asx}+\text{Glx})$  ratio as 10 determined experimentally from the analysed amounts of liberated  $\text{NH}_3$ ,  $\text{Glx}$  (glutamine + glutamic acid) and  $\text{Asx}$  (asparagine + aspartic acid) and the ratio as it should theoretically be on basis of the amino acid composition. The experimentally determined ratio for gluten (77.3%) is 15 in line with the ratio reported by MacRitchie (75.8%).

Table 2. Determination of Gln levels.

		Casein	Whey	Gluten
20	%TN	13.7	14.4	14.0
	mmol $\text{NH}_3$ (=mmol $\text{Asn}+\text{Gln}$ )	100.0	73.8	211.8
	mmol $\text{Asx}$ (analytical data)	49.9	80.2	18.2
25	mmol $\text{Glx}$ (analytical data)	140.7	128.1	239.1
	% $(\text{Asn}+\text{Gln})/(\text{Asx}+\text{Glx})$ (analytical data)	52.5	35.4	77.3
30	% $(\text{Asn}+\text{Gln})/(\text{Asx}+\text{Glx})$ (Amino acid sequence)	50.1	38.3	

From these results it is concluded that the determination of the amount of NH<sub>3</sub> liberated from a protein or a protein hydrolysate is a suitable method to assess the (Asn+Gln)/(Asx+Glx) ratio in a protein based product.

5

The following are non-limiting examples of the present invention.

EXAMPLE 1.

10

Production of a protein hydrolysate using vital gluten.

An 8% dispersion of vital gluten is hydrolysed with 1% (E/S) the commercially available enzyme preparation 15 Orientase 90N (neutral protease ex Quest International Cork, Ireland) at 50°C for 4 hours. The pH is initially set at 7 and during hydrolysis it is not controlled. After hydrolysis the enzyme is inactivated via a heat treatment at 95°C for 1 minute. Residual intact protein and insoluble 20 components are removed via centrifugation for 5 min. at 2500G and the obtained effluent is subsequently ultrafiltered. Preferably membranes with a mol. weight cutoff of 10.000 Dalton are used. The obtained ultrafiltration permeate is concentrated via evaporation 25 and is then spray dried or freeze dried.

The obtained final product is characterised using the above described methods. The results are summarised in Table 3.

Table 3.

5	AN	1.57
	TN	14.80
	FAA	3.54
	PCL	9.3
10	> 10 kD	0.1 †
	5-10 kD	0.1 †
	1-5 kD	2.4 †
	<1 kD	97.4 †
15		Total Amino Acids - mg/g
	Alanine	23.4
	Arginine	27.0
20	Asparagine + Aspartic acid	24.5
	Cysteine	9.0
25	Glutamine + Glutamic acid	279.7
	Glycine	29.9
	Histidine	17.9
30	Isoleucine	24.7
	Leucine	61.3
	Lysine	12.1
	Methionine	12.1
	Phenylalanine	43.4
	Proline	124.8
	Serine	50.6
	Threonine	24.0
	Tyrosine	28.5
35	Valine	28.4
		Free Amino Acids - mg/g
		1.9
		3.7
		0.8
		2.1
		3.2
		0.3
		1.0
		1.9
		6.1
		2.0
		1.1
		3.1
		2.1
		1.2
		0.8
		0.4
		3.7

Evaluation of the hydrolysate in cell tissue cultures.

Three media were composed on basis of the well known RPMI-1640 medium. This medium was prepared as prescribed from 5 the RPMI-1640 select Amine kit from Gibco BRL, Life Technologies Inc., Cat No. 17402-017. The medium was divided in three equal portions which were used as basis for medium 1, 2 and 3.

10 To the media the My additive can be added. This additive contains:

L-glutamine	:	2 mM
Sodium pyruvate	:	1 mM
Gentamycin	:	55 µg/ml
15 β-mercaptop-ethanol	:	50 µM
hypoxanthine	:	100 µM
thymidine	:	15 µM
fetal bovine serum	:	8% (v/v)

20 Medium 1.

To the basic RPMI 1640 medium obtained from the Gibco's select Amine kit the My additive was added.

Medium 2.

25 To the basic RPMI-1640 medium obtained from the Gibco's select Amine kit the My additive without the L-glutamine was added. In stead of L-glutamine as present in the My additive 2.2 g/l of the obtained gluten hydrolysate was added.

30

Medium 3.

To the basic RPMI-1640 medium obtained from the Gibco's select Amine kit the My additive without the L-glutamine was added. In stead thereof 2.2 g/l of a mixture of free

amino acids with the same composition as the obtained gluten hydrolysate was added.

The three media were used to culture following cell lines:

- 5 - U266 : a human myeloma cell line
- SP2/0 : a mouse myeloma cell line
- Anti CD20 : a hybridoma cell line.

To 0.5 ml of a cell suspension which was grown on a  
10 standard medium 4.5 ml of medium 1, 2 or 3 was added. After  
two days 5 ml fresh medium 1, 2 or 3 was added.  
Cell counts were determined directly after adding medium,  
after 1, 5 and 7 days. The results are summarised in Table  
4.

15

From the results it can be seen that the gluten hydrolysate  
from this invention does not give an acute cytotoxicity and  
that the cells can be cultured using the gluten hydrolysate  
according to this invention.

20

Table 4. Cell counts

Counts are given in cells per ml.

5	Cell line	Medium	day 0	after 1 day	after 5 days	after 7 days
10	U266	medium 1	1.7 * 10 <sup>5</sup>	1.5 * 10 <sup>5</sup>	1.6 * 10 <sup>5</sup>	2.6 * 10 <sup>5</sup>
	U266	medium 2	1.2 * 10 <sup>5</sup>	1.2 * 10 <sup>5</sup>	1.9 * 10 <sup>5</sup>	2.0 * 10 <sup>5</sup>
	U266	medium 3	1.1 * 10 <sup>5</sup>	1.3 * 10 <sup>5</sup>	1.4 * 10 <sup>5</sup>	3.1 * 10 <sup>5</sup>
15	SP2/0	medium 1	1.6 * 10 <sup>5</sup>	1.4 * 10 <sup>5</sup>	12.1 * 10 <sup>5</sup>	16.7 * 10 <sup>5</sup>
	SP2/0	medium 2	0.7 * 10 <sup>5</sup>	1.5 * 10 <sup>5</sup>	12.5 * 10 <sup>5</sup>	20.0 * 10 <sup>5</sup>
	Sp2/0	medium 3	0.8 * 10 <sup>5</sup>	0.9 * 10 <sup>5</sup>	14.5 * 10 <sup>5</sup>	19.8 * 10 <sup>5</sup>
20	Anti CD20	medium 1	0.8 * 10 <sup>5</sup>	1.3 * 10 <sup>5</sup>	12.9 * 10 <sup>5</sup>	1.5 * 10 <sup>5</sup>
	Anti CD20	medium 2	1.0 * 10 <sup>5</sup>	1.2 * 10 <sup>5</sup>	11.7 * 10 <sup>5</sup>	16.5 * 10 <sup>5</sup>
	Anti CD20	medium 3	0.9 * 10 <sup>5</sup>	1.7 * 10 <sup>5</sup>	11.7 * 10 <sup>5</sup>	13.5 * 10 <sup>5</sup>

## EXAMPLE 2.

Production of a protein hydrolysate using vital gluten.

An 8% dispersion of vital gluten is hydrolysed with 0.1% (E/S) of the commercially available enzyme preparation pepsin orthana 1:10,000 NF (PCA Diagnostica, Haarlem, The Netherlands) at 50°C for 16 hours. The pH is initially set at 1.5 with hydrochloric acid and is not controlled during further hydrolysis. After hydrolysis the enzyme is inactivated via a heat treatment at 95°C for 1 minute.

Residual intact protein and insoluble components are removed via centrifugation and the obtained effluent is subsequently ultrafiltered. Preferably membranes with a mol. weight cutoff of 10.000 Dalton are used. The obtained 5 ultrafiltration permeate is concentrated via evaporation and is then spray dried or freeze dried.

The obtained final product is characterised using the above described methods. The results are summarised in Table 5.

Table 5.

5	† AN	0.90	
	† TN	12.30	
	† FAA	0.70	
	PCL	11.9	
10	> 10 kD	1.1	
	5-10 kD	1.0	
	1-5 kD	7.4	
	<1 kD	90.5	
15		Total amino acids mg/g	Free amino acids - mg/g
	Alanine	25.4	0.7
	Arginine	24.8	0.0
	Asparagine + aspartic acid	33.9	0.8
	Cysteine	4.4	2.1
20	Glutamine + glutamic acid	162.9	0.0
	Glycine	21.3	0.1
	Histidine	13.5	0.0
25	Isoleucine	25.6	0.0
	Leucine	60.8	0.5
	Lysine	15.2	0.1
	Methionine	13.3	0.1
	Phenylalanine	32.7	0.7
30	Proline	55.0	1.1
	Serine	39.2	0.2
	Threonine	23.0	0.1
	Tryptophan	24.3	0.0
	Tyrosine	28.6	0.4
35	Valine	34.1	0.1

Evaluation of the hydrolysate in cell tissue cultures.

Two media were composed on basis of the well known RPMI-1640 medium. This medium was prepared from the RPMI-1640 5 select Amine kit from Gibco BRL, Life Technologies Inc., Cat No. 17402-017. The medium was divided in two equal portions which were used as basis for medium 1 and 4.

Medium 1.

10 To the basic RPMI-1640 medium obtained from the Gibco's select Amine kit the My additive was added as in example 1.

Medium 4.

15 To the basic RPMI-1640 medium obtained from the Gibco's select Amine kit the My additive without the L-glutamine was added. In stead of L-glutamine as present in the My additive 3.1 g/l of the obtained gluten hydrolysate was added.

20 The two media were used to culture the cell lines described in example 1 following the procedure described in example 1. The results are summarised in Table 6.

**Table 6. Cell counts**

Counts are given in cells per ml.

5	Cell line	Medium	day 0	after 1 day	after 5 days	after 7 days
	U266	medium 1	1.7 * 10 <sup>5</sup>	1.5 * 10 <sup>5</sup>	1.6 * 10 <sup>5</sup>	2.6 * 10 <sup>5</sup>
	U266	medium 4	1.4 * 10 <sup>5</sup>	1.1 * 10 <sup>5</sup>	1.3 * 10 <sup>5</sup>	1.3 * 10 <sup>5</sup>
10	SP2/0	medium 1	1.6 * 10 <sup>5</sup>	1.4 * 10 <sup>5</sup>	12.1 * 10 <sup>5</sup>	16.7 * 10 <sup>5</sup>
	SP2/0	medium 4	1.6 * 10 <sup>5</sup>	1.5 * 10 <sup>5</sup>	13.6 * 10 <sup>5</sup>	14.9 * 10 <sup>5</sup>
	Anti CD20	medium 1	0.8 * 10 <sup>5</sup>	1.3 * 10 <sup>5</sup>	12.9 * 10 <sup>5</sup>	1.5 * 10 <sup>5</sup>
	Anti CD20	medium 4	1.1 * 10 <sup>5</sup>	1.2 * 10 <sup>5</sup>	14.0 * 10 <sup>5</sup>	11.4 * 10 <sup>5</sup>

15 From the results it can be seen that the gluten hydrolysate from this invention does not give an acute cytotoxicity and that the cells can be cultured using the gluten hydrolysate of this invention.

20 EXAMPLE 3

Influence of the hydrolysate on production in cell tissue cultures.

25 The protein hydrolysate described in example 1 was used to compose three media. These media were prepared from the RPMI-1640 select Amine kit from Gibco BRL, Life Technologies Inc., Cat. No. 17402-017 (Glasgow, Scotland).

30 To the media a supplement was added containing:

Sodium pyruvate	:	1 mM
Gentamycin	:	55 µg/ml
β-Mercaptoethanol	:	50 µM
Hypoxanthine	:	100 µM

Thymidine	:	15 $\mu$ M
Fetal bovine serum	:	8 % (v/v)

**Medium 1**

5 The basic RPMI-1640 medium. This medium contains 2 mM glutamine

**Medium 2**

To the basic RPMI-1640 medium, without free amino acids,  
10 1.07 g/l of the gluten hydrolysate described in Example 1, is added. Thus, the medium contains about 2 mM glutamine residues. Additionally the free amino acids asparagine, aspartic acid, glutamic acid, cystine, methionine, isoleucine, lysine, arginine and hydroxyproline were  
15 supplemented in small amounts to compensate for the low levels of these amino acids in the obtained gluten hydrolysate.

**Medium 3**

20 To the basic RPMI-1640 medium, without free amino acids, 2.14 g/l of the gluten hydrolysate described in Example 1, is added. Additionally the free amino acids asparagine, aspartic acid, glutamic acid, cystine, methionine, isoleucine, lysine, arginine and hydroxyproline were  
25 supplemented in small amounts to compensate for the low levels of these amino acids in the obtained gluten hydrolysate.

**Medium 4**

30 To the basic RPMI-1640 medium, without free amino acids, 4.28 g/l of the gluten hydrolysate described in Example 1, is added. Additionally the free amino acids asparagine, aspartic acid, glutamic acid, cystine, methionine, isoleucine, lysine, arginine and hydroxyproline were  
35 supplemented in small amounts to compensate for the low

levels of these amino acids in the obtained gluten hydrolysate.

The above media were used to study the growth performance  
5 of, as well as production by the hybridoma cell line Anti  
CD-20. This cell line was chosen because it is an antibody  
producing cell line with high nutritional requirements. The  
cells were grown on the formulated media in triplo on 25  
cm<sup>2</sup> flasks. The media were refreshed at day 7. The results  
10 are summarized in Table 7

Table 7

Cell counts (expressed as cells per ml).

	Day	Medium 1	Medium 2	Medium 3	Medium 4
5	day 0	$0.67 \times 10^5$	$0.67 \times 10^5$	$0.67 \times 10^5$	$0.67 \times 10^5$
	after 1 day	$1.0 \times 10^5$	$0.8 \times 10^5$	$1.0 \times 10^5$	$0.9 \times 10^5$
	after 2 days	$1.68 \times 10^5$	$1.58 \times 10^5$	$1.26 \times 10^5$	$1.26 \times 10^5$
10	after 3 days	$5.66 \times 10^5$	$3.44 \times 10^5$	$4.44 \times 10^5$	$4.55 \times 10^5$
	after 6 days	$3.17 \times 10^5$	$4.82 \times 10^5$	$7.05 \times 10^5$	$10.4 \times 10^5$
	after 6 days	$0.48 \times 10^5$	$0.72 \times 10^5$	$1.1 \times 10^5$	$1.6 \times 10^5$
15	after 7 days	$1.0 \times 10^5$	$0.9 \times 10^5$	$3.0 \times 10^5$	$5.9 \times 10^5$
	after 8 days	$3.79 \times 10^5$	$2.63 \times 10^5$	$5.89 \times 10^5$	$10.4 \times 10^5$
	after 9 days	$7.44 \times 10^5$	$5 \times 10^5$	$6.66 \times 10^5$	$13.3 \times 10^5$
20	after 10 days	$11.76 \times 10^5$	$4.35 \times 10^5$	$8.23 \times 10^5$	$14.1 \times 10^5$
	after 14 days	$0.6 \times 10^5$	$3.12 \times 10^5$	$2.5 \times 10^5$	$4.12 \times 10^5$

All the test conditions of table 7 were analysed with ELISA on the antibody production. The results are summarized in Table 8

5 Table 8

Antibody production of hybridoma Anti CD-20 on the formulated media. The antibody concentrations IgG of the supernatants are expressed in  $\mu$ g/ml.

	Day	Medium 1	Medium 2	Medium 3	Medium 4
10	after 1 day	0.9	1.9	1.8	1.6
	after 2 days	2.2	1.9	3.0	3.3
15	after 3 days	5.0	2.8	5.7	4.0
	after 6 days	18.9	9.0	30.6	22.4
20	after 7 days	5.2	2.9	10.7	8.1
	after 8 days	8.5	5.2	18.7	13.4
25	after 9 days	9.7	5.2	22.2	23.3
	after 10 days	13.7	6.8	21.6	16.0
	after 14 days	23.8	9.5	51.0	44.4

## EXAMPLE 4

Influence of the hydrolysate in cell tissue cultures.

5

The protein hydrolysate described in Example 1 was used to compose two media. These media was prepared from the RPMI-1640 select Amine kit from Gibco BRL, Life Technologies Inc., Cat. No. 17402-017 (Glasgow, Scotland).

10

To the media a supplement was added. This supplement contains:

Sodium pyruvate	:	1 mM
Gentamycin	:	55 µg/ml
15 $\beta$ -Mercaptoethanol	:	50 $\mu$ M
Hypoxanthine	:	100 $\mu$ M
Thymidine	:	15 $\mu$ M
Fetal bovine serum	:	8 % (v/v)

20    Medium 1

The basic RPMI-1640 medium, which contains 2 mM glutamine.

## Medium 2

To the basic RPMI-1640 medium, without free amino acids, 25 1.07 g/l of the gluten hydrolysate described in example 1, is added. Thus, the medium contains about 2 mM glutamine residues.

## Medium 3

30    To the basic RPMI-1640 medium, without free amino acids, 2.14 g/l of the gluten hydrolysate described in example 1, is added. Thus, this medium contains about 4mM glutamine residues.

The above media were used to study the growth performance of, as well as production by the hybridoma cell line Anti CD-20. The cells were grown on the formulated media in triplo on 25 cm<sup>2</sup> flasks. The media were refreshed at day 7.

5 The results are summarized in Table 9

**Table 9. Cell counts**

Counts are given in cells per ml.

	Day	Medium 1	Medium 2	Medium 3
10	day 0	$1.3 \cdot 10^5$	$1.3 \cdot 10^5$	$1.3 \cdot 10^5$
	after 1 day	$1.9 \cdot 10^5$	$1.8 \cdot 10^5$	$2.0 \cdot 10^5$
	after 2 days	$5.05 \cdot 10^5$	$5.89 \cdot 10^5$	$5.7 \cdot 10^5$
	after 3 days	$10.1 \cdot 10^5$	$6.88 \cdot 10^5$	$6.0 \cdot 10^5$
	after 4 days	$14.1 \cdot 10^5$	$4.47 \cdot 10^5$	$5.1 \cdot 10^5$
	after 9 days	$2.0 \cdot 10^4$	$1.0 \cdot 10^4$	$1.3 \cdot 10^5$

All the test conditions of table 9 were analysed with ELISA on the antibody production. The results are summarized in  
20 Table 10.

**Table 10**

Antibody production of Hybridoma Anti CD-20 on the formulated media. The antibody concentration IgG of the 5 supernatants were expressed in  $\mu$ g/ml.

	Day	Medium 1	Medium 2	Medium 3
10	after 1 day	1.9	2.7	4.4
	after 2 days	4.4	6.0	7.9
	after 3 days	8.3	10.4	11.2
	after 4 days	13.6	12.7	16.8
	after 9 days	18.5	13.0	52.1

Example 3 as well as Example 4 show that using the protein 15 hydrolysate as the source of glutamine in most cases gives improved growth compared to the standard RPMI-1640 culture medium containing free amino acids. The effect on production of antibodies is even more pronounced, even in those cases where the number of cells is not markedly 20 different between the standard medium and the media containing the protein hydrolysate according to the invention.

## CLAIMS

1. A method for in vitro maintaining or growing eucaryotic cells by use of a culture medium comprising a glutamine containing protein hydrolysate, obtained by enzymatic hydrolysis of a protein material, wherein the protein hydrolysate has a free amino acid level of less than 15% by weight of the total proteinaceous material and the peptides have a molecular weight below 44 kD
- 5
- 10
2. A method according to claim 1 wherein 90% by weight of the protein hydrolysate has molecular weight below 1000 D.
- 15
3. A method according to claims 1 or 2 wherein the average peptide chain length in the protein hydrolysate is less than 15 amino acid residues.
- 20 4. A method according to claim 3 wherein the average peptide chain length in the protein hydrolysate is less than 10 amino acid residues.
- 5.
- 25
6. A method according to claims 1-4 wherein the protein hydrolysate has a free amino acid level of less than 4% by weight of the total proteinaceous material.
- 30
7. A method according to claims 1-6 wherein the protein material is a cereal protein.

8. A method according to claim 7 wherein the protein material is a wheat gluten or a subfraction thereof.
9. A culture medium for in vitro maintaining or growing eucaryotic cells which comprises a glutamine containing protein hydrolysate, obtained by enzymatic hydrolysis of a protein material, wherein the protein hydrolysate has a free amino acid level of less than 15% by weight of the total proteinaceous material and the peptides have a molecular weight below 44 kD.
10. A culture medium according to claim 9 wherein at least 90% by weight of the protein hydrolysate has molecular weight below 1000 D.
11. A culture medium according to claims 9 or 10 wherein the average peptide chain length in the protein hydrolysate is less than 15 amino acid residues.
12. A culture medium according to claim 11 wherein the average peptide chain length in the protein hydrolysate is less than 10 amino acid residues.
13. A culture medium according to claims 9-12 wherein the protein hydrolysate has a free amino acid level of less than 4% by weight of the total proteinaceous material.
14. A culture medium according to claims 9-13 wherein the protein hydrolysate contains 20% by weight or more of glutamine residues.
15. A culture medium according to claims 9-14 wherein the protein material is a cereal protein.

16. A culture medium according to claim 15 wherein the protein material is a wheat gluten or a subfraction thereof.
17. A kit for in vitro maintaining or growing eucaryotic cells which comprises a container and a culture medium according to any one of claims 9-16.
- 18 A kit according to claim 17 in which the culture medium is a sterile ready to use liquid.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 96/00720

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N5/02

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 235 772 (RONNY-HUGO L. LUNDIN ET AL.) 25 November 1980 cited in the application see column 1, line 5 - line 21 see column 3, line 34 - line 57 ---	1-6,9-14
A	Database PAJ; 8 May 1990 MIHARA AKIRA ET AL.: "Culture medium" & JP-A-2049579 (Kyowa Hakko Kogyo Co. Ltd.) 19 February 1990 XP002006666 ---	1,7-9, 15-18
A	EP,A,0 220 379 (PFRIMMER & CO. PHARMAZEUISCHE WERKE ERLANGEN GMBH & CO. KG) 6 May 1987 see page 2, line 46 - page 4, line 26 ---	1-4,6, 9-12,14, 17,18 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*'A' document defining the general state of the art which is not considered to be of particular relevance
- \*'E' earlier document but published on or after the international filing date
- \*'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*'O' document referring to an oral disclosure, use, exhibition or other means
- \*'P' document published prior to the international filing date but later than the priority date claimed

- \*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*'A' document member of the same patent family

Date of the actual completion of the international search

26 June 1996

Date of mailing of the international search report

23. 07. 96

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+ 31-70) 340-3016

Authorized officer

Montero Lopez, B

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 96/00720

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>JOURNAL OF IMMUNOLOGICAL METHODS, vol. 166, no. 1, 1993, NEW YORK US, pages 85-91, XP002006664</p> <p>S. HEENEMAN ET AL.: "The concentrations of glutamine and ammonia in commercially available cell culture media" cited in the application see abstract see page 90, left-hand column, paragraph 2 - right-hand column, paragraph 1 ---</p>	1-18
A	<p>JOURNAL OF FOOD BIOCHEMISTRY, vol. 16, no. 4, 1993, pages 235-248, XP002006665</p> <p>SOICHI TANABE ET AL.: "Production of a high-glutamine oligopeptide fraction from gluten by enzymatic treatment and evaluation of its nutritional effect on the small intestine of rats" cited in the application see abstract see page 240, paragraph 1 - page 243, paragraph 2 -----</p>	8-16

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
**PCT/EP 96/00720**

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
<b>US-A-4235772</b>	<b>25-11-80</b>	<b>NONE</b>		
<b>EP-A-220379</b>	<b>06-05-87</b>	<b>DE-A-</b>	<b>3538310</b>	<b>30-04-87</b>